Biodesix Inc. [NASDAQ: BDSX] surged by $2.01 during the normal trading session on Friday and reaching a high of $28.81 during the day while it closed the day at $28.00. The company report on January 13, 2021 that HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization.
Initial program to focus on development of a companion diagnostic for HiberCell’s novel immunotherapy, Imprime PGG, to aid in patient selection across multiple oncology programs.
HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, announced an agreement with Biodesix, Inc. (Nasdaq: BDSX) to further the development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic in future registrational trials in breast cancer for Imprime PGG programs. Terms of the partnership were not disclosed.
The market cap for BDSX stock reached $689.92 million, with 24.64 million shares outstanding and 17.95 million shares in the current float. Compared to the average trading volume of 246.41K shares, BDSX reached a trading volume of 259487 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Biodesix Inc. [BDSX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BDSX shares is $23.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BDSX stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for Biodesix Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 23, 2020. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Overweight. The new note on the price target was released on November 23, 2020, representing the official price target for Biodesix Inc. stock. Previously, the target price had yet another raise to $26, while Canaccord Genuity analysts kept a Buy rating on BDSX stock.
The Average True Range (ATR) for Biodesix Inc. is set at 1.99, with the Price to Sales ratio for BDSX stock in the period of the last 12 months amounting to 25.74.
BDSX stock trade performance evaluation
Biodesix Inc. [BDSX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.14.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BDSX stock in for the last two-week period is set at 78.94, with the RSI for the last a single of trading hit 84.56, and the three-weeks RSI is set at 74.92 for Biodesix Inc. [BDSX]. The present Moving Average for the last 50 days of trading for this stock 17.11, while it was recorded at 24.53 for the last single week of trading.
Biodesix Inc. [BDSX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Biodesix Inc. [BDSX] shares currently have an operating margin of -92.16 and a Gross Margin at +75.26. Biodesix Inc.’s Net Margin is presently recorded at -125.15.
Receivables Turnover for the company is 6.84 with a Total Asset Turnover recorded at a value of 0.61.Biodesix Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 0.30.
Biodesix Inc. [BDSX]: Insider Ownership positions
Positions in Biodesix Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 1 institutional holders increased their position in Biodesix Inc. [NASDAQ:BDSX] by around 31 shares. Additionally, 0 investors decreased positions by around 0 shares, while 0 investors held positions by with 0 shares. The mentioned changes placed institutional holdings at 31 shares, according to the latest SEC report filing. BDSX stock had 1 new institutional investments in for a total of 31 shares, while 0 institutional investors sold positions of 0 shares during the same period.